公开(公告)号：US11707533B2

公开(公告)日：2023-07-25

申请号：US16940326

申请日：2020-07-27

申请人： LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

发明人： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-Na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K47/6849 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2803

摘要： The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US20230405139A1

公开(公告)日：2023-12-21

申请号：US18209299

申请日：2023-06-13

申请人： LegoChem Biosciences, Inc. ,  ABL Bio, Inc.

发明人： Yun-Hee Park ,  Ho Young Song ,  Hyun Min Ryu ,  Sung Min Kim ,  Ju Yuel Baek ,  Ji Hye Oh ,  Nara Han ,  Hyoung Rae Kim ,  Kyung Eun Park ,  Hyeun Joung Lee ,  Ju Young Lee ,  Dae Hyuck Kang ,  Young-Jae Yang ,  Ji-na You ,  Yong Zu Kim ,  Chang Sun Lee ,  Jeiwook Chae ,  Jinwon Jung ,  Juhee Kim ,  Bora Lee ,  Daehae Song ,  Byungje Sung ,  Donghoon Yeom ,  Jaehyun Eom ,  Youngeun Hong ,  Jinhyung Ahn ,  Yangsoon Lee ,  Kyungjin Park ,  Jiseon Yoo ,  Minji Park

IPC分类号： A61K47/68 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K47/6849 ,  A61P35/00 ,  A61K47/6803 ,  C07K16/2803

摘要： The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.